Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models

Chao Jian, Mei Juan Tu, Pui Yan Ho, Zhijian Duan, Qianyu Zhang, Jing Xin Qiu, Ralph W deVere White, Theodore Wun, Primo N Lara, Kit Lam, Ai Xi Yu, Aiming Yu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target. This study was aimed at assessing the hypothesis that drugs could be rationally combined to co-target critical DNA, RNA and protein molecules to achieve "saturation attack" against metastasis. Independent actions of the model drugs DNA-intercalating doxorubicin, RNA-interfering miR- 34a and protein-inhibiting sorafenib on DNA replication, RNA translation and protein kinase signaling in highly metastatic, human osteosarcoma 143B cells were demonstrated by the increase of γH2A.X foci formation, reduction of c-MET expression and inhibition of Erk1/2 phosphorylation, respectively, and optimal effects were found for triple-drug combination. Consequently, triple-drug treatment showed a strong synergism in suppressing 143B cell proliferation and the greatest effects in reducing cell invasion. Compared to single- and dual-drug treatment, triple-drug therapy suppressed pulmonary metastases and orthotopic osteosarcoma progression to significantly greater degrees in orthotopic osteosarcoma xenograft/spontaneous metastases mouse models, while none showed significant toxicity. In addition, tripledrug therapy improved the overall survival to the greatest extent in experimental metastases mouse models. These findings demonstrate co-targeting of DNA, RNA and protein molecules as a novel therapeutic strategy for the treatment of metastasis.

Original languageEnglish (US)
Pages (from-to)30742-30755
Number of pages14
JournalOncotarget
Volume8
Issue number19
DOIs
StatePublished - 2017

Fingerprint

Osteosarcoma
RNA
Neoplasm Metastasis
Lung
DNA
Proteins
Pharmaceutical Preparations
Therapeutics
Drug Combinations
DNA Replication
Heterografts
Protein Kinases
Neoplasms
Phosphorylation
Cell Proliferation
Drug Therapy
Survival
Mortality

Keywords

  • Doxorubicin
  • Metastasis
  • MiR-34a
  • Pathology Section
  • Sorafenib
  • Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. / Jian, Chao; Tu, Mei Juan; Ho, Pui Yan; Duan, Zhijian; Zhang, Qianyu; Qiu, Jing Xin; deVere White, Ralph W; Wun, Theodore; Lara, Primo N; Lam, Kit; Yu, Ai Xi; Yu, Aiming.

In: Oncotarget, Vol. 8, No. 19, 2017, p. 30742-30755.

Research output: Contribution to journalArticle

@article{60118a5fad524fbba70547c1aba4291f,
title = "Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models",
abstract = "Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target. This study was aimed at assessing the hypothesis that drugs could be rationally combined to co-target critical DNA, RNA and protein molecules to achieve {"}saturation attack{"} against metastasis. Independent actions of the model drugs DNA-intercalating doxorubicin, RNA-interfering miR- 34a and protein-inhibiting sorafenib on DNA replication, RNA translation and protein kinase signaling in highly metastatic, human osteosarcoma 143B cells were demonstrated by the increase of γH2A.X foci formation, reduction of c-MET expression and inhibition of Erk1/2 phosphorylation, respectively, and optimal effects were found for triple-drug combination. Consequently, triple-drug treatment showed a strong synergism in suppressing 143B cell proliferation and the greatest effects in reducing cell invasion. Compared to single- and dual-drug treatment, triple-drug therapy suppressed pulmonary metastases and orthotopic osteosarcoma progression to significantly greater degrees in orthotopic osteosarcoma xenograft/spontaneous metastases mouse models, while none showed significant toxicity. In addition, tripledrug therapy improved the overall survival to the greatest extent in experimental metastases mouse models. These findings demonstrate co-targeting of DNA, RNA and protein molecules as a novel therapeutic strategy for the treatment of metastasis.",
keywords = "Doxorubicin, Metastasis, MiR-34a, Pathology Section, Sorafenib, Therapy",
author = "Chao Jian and Tu, {Mei Juan} and Ho, {Pui Yan} and Zhijian Duan and Qianyu Zhang and Qiu, {Jing Xin} and {deVere White}, {Ralph W} and Theodore Wun and Lara, {Primo N} and Kit Lam and Yu, {Ai Xi} and Aiming Yu",
year = "2017",
doi = "10.18632/oncotarget.16372",
language = "English (US)",
volume = "8",
pages = "30742--30755",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "19",

}

TY - JOUR

T1 - Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models

AU - Jian, Chao

AU - Tu, Mei Juan

AU - Ho, Pui Yan

AU - Duan, Zhijian

AU - Zhang, Qianyu

AU - Qiu, Jing Xin

AU - deVere White, Ralph W

AU - Wun, Theodore

AU - Lara, Primo N

AU - Lam, Kit

AU - Yu, Ai Xi

AU - Yu, Aiming

PY - 2017

Y1 - 2017

N2 - Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target. This study was aimed at assessing the hypothesis that drugs could be rationally combined to co-target critical DNA, RNA and protein molecules to achieve "saturation attack" against metastasis. Independent actions of the model drugs DNA-intercalating doxorubicin, RNA-interfering miR- 34a and protein-inhibiting sorafenib on DNA replication, RNA translation and protein kinase signaling in highly metastatic, human osteosarcoma 143B cells were demonstrated by the increase of γH2A.X foci formation, reduction of c-MET expression and inhibition of Erk1/2 phosphorylation, respectively, and optimal effects were found for triple-drug combination. Consequently, triple-drug treatment showed a strong synergism in suppressing 143B cell proliferation and the greatest effects in reducing cell invasion. Compared to single- and dual-drug treatment, triple-drug therapy suppressed pulmonary metastases and orthotopic osteosarcoma progression to significantly greater degrees in orthotopic osteosarcoma xenograft/spontaneous metastases mouse models, while none showed significant toxicity. In addition, tripledrug therapy improved the overall survival to the greatest extent in experimental metastases mouse models. These findings demonstrate co-targeting of DNA, RNA and protein molecules as a novel therapeutic strategy for the treatment of metastasis.

AB - Metastasis is a major cause of mortality for cancer patients and remains as the greatest challenge in cancer therapy. Driven by multiple factors, metastasis may not be controlled by the inhibition of single target. This study was aimed at assessing the hypothesis that drugs could be rationally combined to co-target critical DNA, RNA and protein molecules to achieve "saturation attack" against metastasis. Independent actions of the model drugs DNA-intercalating doxorubicin, RNA-interfering miR- 34a and protein-inhibiting sorafenib on DNA replication, RNA translation and protein kinase signaling in highly metastatic, human osteosarcoma 143B cells were demonstrated by the increase of γH2A.X foci formation, reduction of c-MET expression and inhibition of Erk1/2 phosphorylation, respectively, and optimal effects were found for triple-drug combination. Consequently, triple-drug treatment showed a strong synergism in suppressing 143B cell proliferation and the greatest effects in reducing cell invasion. Compared to single- and dual-drug treatment, triple-drug therapy suppressed pulmonary metastases and orthotopic osteosarcoma progression to significantly greater degrees in orthotopic osteosarcoma xenograft/spontaneous metastases mouse models, while none showed significant toxicity. In addition, tripledrug therapy improved the overall survival to the greatest extent in experimental metastases mouse models. These findings demonstrate co-targeting of DNA, RNA and protein molecules as a novel therapeutic strategy for the treatment of metastasis.

KW - Doxorubicin

KW - Metastasis

KW - MiR-34a

KW - Pathology Section

KW - Sorafenib

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85019158433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019158433&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.16372

DO - 10.18632/oncotarget.16372

M3 - Article

AN - SCOPUS:85019158433

VL - 8

SP - 30742

EP - 30755

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 19

ER -